Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.
Vivek Subbiah(Sarah Cannon), Yan Xing(Peking University), Carey K. Anders(Duke University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Kim Ingram(Pfizer (United States)), Martin Gutierrez(Hackensack University Medical Center), Colleen Oliver(Pfizer (United States)), Sunandana Chandra(Northwestern University), Ibiayi Dagogo‐Jack(Massachusetts General Hospital), Kati Maharry(Peter MacCallum Cancer Centre), Micaela B. Reddy(Pfizer (United States)), Dale Nepert(Pfizer (United States)), Elizabeth I. Buchbinder(Massachusetts General Hospital), Varun Monga(University of Iowa), George Ansstas(Washington University in St. Louis), Eli L. Diamond(Memorial Sloan Kettering Cancer Center), Katy K. Tsai(University of California, San Francisco), Peter Forsyth(Moffitt Cancer Center), Meredith McKean(Sarah Cannon)
Cited by 8
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k